<DOC>
	<DOC>NCT01006590</DOC>
	<brief_summary>The study will evaluate the efficacy and tolerability of saxagliptin compared to uptitration of metformin in patients with type 2 diabetes who have inadequate glycaemic control on a submaximal dose of metformin.</brief_summary>
	<brief_title>Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Provision of signed informed consent Established clinical diagnosis of type 2 diabetes. Treatment with a stable dose of metformin monotherapy (15001700 mg/day) for at least 8 weeks prior to visit 1. HbA1c ≥7.0% and ≤10.0% Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar nonketonic coma. Renal impairment as defined by a creatinine clearance &lt;60 mL/min/1.73 m2 Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Randomised</keyword>
	<keyword>Double-blind</keyword>
</DOC>